Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia
ConclusionsThis study showed that natalizumab dominated fingolimod with lower costs and higher QALYs in patients with high-activity RRMS. These results are consistent with previous published international literature.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research
More News: Brain | Colombia Health | Disability | Gilenya | International Medicine & Public Health | Multiple Sclerosis | Neurology | Study | Tysabri